Various studies have reported that RIG-I recognizes and binds to lncRNAs to manifest nonspecific antiviral, antitumor, and other immunoprotective effects (RIG-I is a tumor suppressor and biomarker of IFN-α efficacy in HCC, 2014; Hou et al., 2021; Johnson et al., 2021; Li and Wu, 2021). Here, RIGI is linked to hepatocellular carcinoma.